Longeveron, Inc. (LGVN)
6.75
-0.05
(-0.74%)
USD |
NASDAQ |
Aug 28, 16:00
6.75
0.00 (0.00%)
After-Hours: 18:01
Longeveron Shareholders Equity (Quarterly) : 10.40M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.40M |
| March 31, 2026 | 16.03M |
| December 31, 2025 | 5.675M |
| September 30, 2025 | 9.966M |
| June 30, 2025 | 12.66M |
| March 31, 2025 | 17.16M |
| December 31, 2024 | 21.89M |
| September 30, 2024 | 25.63M |
| June 30, 2024 | 14.91M |
| March 31, 2024 | 3.041M |
| December 31, 2023 | 6.841M |
| September 30, 2023 | 6.732M |
| June 30, 2023 | 11.36M |
| March 31, 2023 | 16.42M |
| Date | Value |
|---|---|
| December 31, 2022 | 20.60M |
| September 30, 2022 | 24.72M |
| June 30, 2022 | 29.48M |
| March 31, 2022 | 34.41M |
| December 31, 2021 | 37.55M |
| September 30, 2021 | 22.43M |
| June 30, 2021 | 24.75M |
| March 31, 2021 | 26.60M |
| December 31, 2020 | 1.957M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 4.445M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 15.49M |
| Total Liabilities (Quarterly) | 5.085M |
| Debt to Equity Ratio | 0.0559 |
| Current Ratio | 2.629 |
| Net Debt Paydown Yield | 0.64% |